У нас вы можете посмотреть бесплатно Talquetamab in Pts with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1 или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Dr. Ajai Chari, Mt. Sinai School of Medicine, presents an abstract on Talquetamab in patients with relapsed refractory multiple myeloma. Background: G protein-coupled receptor family C group 5 member D (GPRC5D) has limited expression in normal human tissue but is highly expressed on malignant plasma cells, making it a promising immunotherapy target for patients (pts) with multiple myeloma (MM). Talquetamab is a first-in-class, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D and CD3 receptors. MonumenTAL-1 is a phase 1/2 trial (NCT03399799/NCT04634552) of talquetamab in pts with RRMM. In phase 1 of MonumenTAL-1, collective safety, efficacy, pharmacokinetic (PK), and pharmacodynamic (PD) data supported selection of 2 recommended phase 2 doses (RP2Ds) for talquetamab: 0.405 mg/kg subcutaneous (SC) weekly (QW) and 0.8 mg/kg SC every other week (Q2W). Here, we report results for pts treated at these RP2Ds in phase 1 and 2 of MonumenTAL-1. Conclusions: Talquetamab demonstrated robust efficacy and manageable safety in pts with heavily pretreated RRMM. Additional phase 1 studies (NCT04586426; NCT04108195; NCT05050097) are evaluating talquetamab in combination with other agents in pts with RRMM. Authors: Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique C. Minnema, MD, PhD, Jesus Berdeja, MD, Albert Oriol, Niels WCJ Van De Donk, MD, Paula Rodriguez Otero, Elham Askari, Maria-Victoria Mateos, MD, Luciano J. Megala Costa, MD, PhD, Jo Caers, PhD, Leo Rasche, MD, Amrita Y. Krishnan, MD, FACP, Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Katharine S. Gries, PhD, PharmD, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Christoph Heuck, Jesús San-Miguel, MD, PhD and Philippe Moreau, MD ASH Abstract #157: https://ash.confex.com/ash/2022/webpr... _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel: / imfmyeloma Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma | / myeloma Twitter: @IMFMyeloma | / imfmyeloma Instagram: @imfmyeloma | / imfmyeloma LinkedIn: / international-myeloma-foundation Support the IMF | Donate Now! https://secure.myeloma.org/page/40697... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.